{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:12:54Z","timestamp":1760058774200,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objective: The objective of this study was to calculate the epidemiological impact of metabolic dysfunction associated with fatty liver disease (MAFLD) and hepatic fibrosis in primary care (PC). Secondarily, we assessed the correlation between serological markers (FIB-4, ELF test), abdominal ultrasound, and transient elastography in the early detection of MAFLD. Methods: An observational prospective study was designed to determine the prevalence of MAFLD and to assess the correlation between complementary tests. Patients were recruited from five health centres. Eligible participants were adults aged between 18 and 70 years with at least one metabolic risk factor, including being overweight (BMI 25\u201329.9 kg\/m2) or obese (BMI &gt; 30 kg\/m2), or diagnosed with type 2 diabetes mellitus (T2DM), dyslipidemia, or metabolic syndrome. The prevalence of MAFLD was calculated. Correlations between diagnostic tests were evaluated using Pearson\u2019s correlation coefficient. Results: A total of 98 patients was included. Using CAP (controlled attenuation parameter) measurements, the prevalence of MAFLD was found to be 67.7%, and the prevalence of hepatic fibrosis was 6.5%. The correlation between conventional ultrasound and CAP from FibroScan\u00ae for the diagnosis of MAFLD was low and not statistically significant (0.160 [95% CI: \u22120.100; 0.400], p = 0.226). In contrast, the diagnosis of hepatic fibrosis using FibroScan\u00ae in PC showed a high correlation with diagnoses performed in gastroenterology department (0.942 [95% CI: 0.844; 0.979], p &lt; 0.001). The correlation with biochemical markers was low and not statistically significant for both FIB-4 (0.125 [95% CI: \u22120.129; 0.363], p = 0.334) and the ELF test (0.159 [95% CI: \u22120.111; 0.407], p = 0.246). Conclusions: Two out of three patients with metabolic risk factors were diagnosed with MAFLD, while hepatic fibrosis diagnoses were uncommon. These results reinforce the validity of using FibroScan\u00ae in PC.<\/jats:p>","DOI":"10.3390\/jcm14093089","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:50:17Z","timestamp":1745992217000},"page":"3089","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnosis and Monitoring of Metabolic Dysfunction Associated with Fatty Liver Disease in Primary Care Patients with Risk Factors\u2014EsteatoGal Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1308-6010","authenticated-orcid":false,"given":"Nerea","family":"S\u00e1nchez-Varela","sequence":"first","affiliation":[{"name":"Centro de Salud Concepci\u00f3n Arenal, \u00c1rea Sanitaria Integrada Santiago de Compostela, 15701 Santiago de Compostela, A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4486-2820","authenticated-orcid":false,"given":"Sergio","family":"Cinza-Sanjurjo","sequence":"additional","affiliation":[{"name":"Centro de Salud Milladoiro, \u00c1rea Sanitaria Integrada Santiago de Compostela, 15895 O Milladoiro, A Coru\u00f1a, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (IDIS), 15706 Santiago de Compostela, A Coru\u00f1a, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Madrid, Spain"},{"name":"Departamento de Medicina, Universidad de Santiago de Compostela (USC), 15782 Santiago de Compostela, A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Danif-Ferreira","sequence":"additional","affiliation":[{"name":"Centro de Salud A Estrada, \u00c1rea Sanitaria Integrada Santiago de Compostela, 36680 A Estrada, Pontevedra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liseth I.","family":"Medina Araujo","sequence":"additional","affiliation":[{"name":"Centro de Salud Concepci\u00f3n Arenal, \u00c1rea Sanitaria Integrada Santiago de Compostela, 15701 Santiago de Compostela, A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego G.","family":"Mosteiro Migu\u00e9ns","sequence":"additional","affiliation":[{"name":"Centro de Salud Concepci\u00f3n Arenal, \u00c1rea Sanitaria Integrada Santiago de Compostela, 15701 Santiago de Compostela, A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2929-8739","authenticated-orcid":false,"given":"Daniel","family":"Rey-Aldana","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (IDIS), 15706 Santiago de Compostela, A Coru\u00f1a, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Madrid, Spain"},{"name":"Departamento de Medicina, Universidad de Santiago de Compostela (USC), 15782 Santiago de Compostela, A Coru\u00f1a, Spain"},{"name":"Centro de Salud A Estrada, \u00c1rea Sanitaria Integrada Santiago de Compostela, 36680 A Estrada, Pontevedra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-7683","authenticated-orcid":false,"given":"Manuel","family":"Portela-Romero","sequence":"additional","affiliation":[{"name":"Centro de Salud Concepci\u00f3n Arenal, \u00c1rea Sanitaria Integrada Santiago de Compostela, 15701 Santiago de Compostela, A Coru\u00f1a, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (IDIS), 15706 Santiago de Compostela, A Coru\u00f1a, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Madrid, Spain"},{"name":"Departamento de Medicina, Universidad de Santiago de Compostela (USC), 15782 Santiago de Compostela, A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the EsteatoGal Researchers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sieddek, A.S., Muhammed, R.R., and Attia, D. (2024). Screening of Metabolic-Associated Fatty Liver Disease in General Population Attending Outpatient Clinic. SN Compr. Clin. Med., 6.","DOI":"10.1007\/s42399-023-01628-4"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"103767","DOI":"10.1016\/j.numecd.2024.10.006","article-title":"Elevated Concurrent Carotid Atherosclerosis Rates in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Compared to Non-Alcoholic Fatty Liver Disease (NAFLD): A Cross-Sectional Observational Study","volume":"35","author":"Chung","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104024","DOI":"10.1016\/j.numecd.2025.104024","article-title":"Comparative Association of MAFLD\/MASLD and Subtypes with Cardiovascular Diseases Outcomes","volume":"35","author":"Jin","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hep.24356","article-title":"Fatty Liver Index and Mortality: The Cremona Study in the 15th Year of Follow-Up","volume":"54","author":"Calori","year":"2011","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/ceh.2018.73155","article-title":"The Influence of NAFLD on the Risk of Atherosclerosis and Cardiovascular Diseases","volume":"4","author":"Piekarska","year":"2018","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Hadadi, I., Adam, M., Musa, M.J., Gareeballah, A., Alqahtani, M.M., Kanbayti, I.H., and Hazazi, A. (2025). Exploring the Prevalence and Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus Patients Using Ultrasound: A Cross-Sectional Study. Curr. Med. Imaging, 21.","DOI":"10.2174\/0115734056354807241217043210"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.31146\/1682-8658-ecg-182-10-88-95","article-title":"Cardiovascular Comorbidity in Non-Alcoholic Fatty Liver Disease","volume":"10","author":"Timakova","year":"2020","journal-title":"Exp. Clin. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOG.0000000000000823","article-title":"Metabolic Dysfunction-Associated Fatty Liver Disease: A Year in Review","volume":"38","author":"Alharthi","year":"2022","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The Economic and Clinical Burden of Nonalcoholic Fatty Liver Disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.2337\/dc25-S004","article-title":"4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the Metabolic Syndrome","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 Risk Prediction Algorithms: New Models to Estimate 10-Year Risk of Cardiovascular Disease in Europe","volume":"42","author":"Achenbach","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP Risk Prediction Algorithms: Estimating Incident Cardiovascular Event Risk in Older Persons in Four Geographical Risk Regions","volume":"42","author":"Cooney","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/2230-8210.146874","article-title":"Assessment of Insulin Sensitivity\/Resistance","volume":"19","author":"Gutch","year":"2015","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s40618-021-01501-y","article-title":"Prevalence of Hepatic Steatosis in Patients with Type 2 Diabetes and Response to Glucose-Lowering Treatments. A Multicenter Retrospective Study in Italian Specialist Care","volume":"44","author":"Morieri","year":"2021","journal-title":"J. Endocrinol. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jhep.2022.06.016","article-title":"Low Accuracy of FIB-4 Test to Identify People with Diabetes at Low Risk of Advanced Fibrosis","volume":"77","author":"Gracen","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced Liver Fibrosis Test for the Non-Invasive Diagnosis of Fibrosis in Patients with NAFLD: A Systematic Review and Meta-Analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.ultrasmedbio.2021.06.002","article-title":"Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper","volume":"47","author":"Ferraioli","year":"2021","journal-title":"Ultrasound Med. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s11739-022-02966-2","article-title":"Liver Stiffness Measurement Identifies Subclinical Myocardial Dysfunction in Non-Advanced Non-Alcoholic Fatty Liver Disease Patients without Overt Heart Disease","volume":"17","author":"Sonaglioni","year":"2022","journal-title":"Intern. Emerg. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Stefanska, A., Bergmann, K., Suwa\u0142a, S., Mankowska-Cyl, A., Kozinski, M., Junik, R., Krintus, M., and Panteghini, M. (2024). Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease. Metabolites, 14.","DOI":"10.3390\/metabo14010052"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kang, Y.-W., Baek, Y.-H., and Moon, S.-Y. (2024). Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Diagnostics, 14.","DOI":"10.3390\/diagnostics14222517"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jun, B.G., Park, W.Y., Park, E.J., Jang, J.Y., Jeong, S.W., Lee, S.-H., Kim, S.G., Cha, S.-W., Kim, Y.S., and Cho, Y.D. (2017). A Prospective Comparative Assessment of the Accuracy of the FibroScan in Evaluating Liver Steatosis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182784"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/3089\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:24:25Z","timestamp":1760030665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/3089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14093089"],"URL":"https:\/\/doi.org\/10.3390\/jcm14093089","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}